Literature DB >> 10760428

Radiotherapy for lung cancer: target splitting by asymmetric collimation enables reduction of radiation doses to normal tissues and dose escalation.

K Wurstbauer1, H Deutschmann, M Kranzinger, F Merz, H Rahim, F Sedlmayer, H D Kogelnik.   

Abstract

PURPOSE: This study was performed to develop a method of reducing the radiation doses to normal thoracic tissues, increasing the target dose, especially in the primary radiotherapy of non-small cell lung cancer (NSCLC), and to evaluate acute/subacute toxicity of dose escalation. METHODS AND MATERIALS: From December 1195 to March 1998, the technique of target splitting has been applied to 58 patients. In this period, 30 patients were treated with doses > 80 Gy (ICRU-specification, mean 85.1 Gy, range 80. 1-90.2 Gy). The target volume is split into a cranial part (e.g., upper mediastinum) and a caudal part (e.g., primary tumor and middle mediastinum). Both volumes are planned and treated independently, using conformal irradiation techniques for both parts with half-collimated fields to prevent over- or underdosage in the junction plane. After fine-adjustment of the jaws, a verification film, exposed in a polymethylmethacrylate (PMMA) phantom, demonstrates the homogeneity of dose in the entire target volume. For comparison with conventional techniques, planning to identical doses is performed for 5 patients. Dose-volume histograms (DHVs) for normal lung tissue are presented for both methods.
RESULTS: The irradiated volume of normal tissue of the ipsilateral lung can be lowered at dose levels > or = 65, > or =45 Gy, and > or = 20 Gy to values of 37% (range 25-54%), 49% (range 46-54%), and 86% (range 55-117%), respectively. Other organs at risk, such as heart or esophagus, can also be spared significantly. Only 1 patient showed a transient grade 3 toxicity (pneumonitis), and there where no grade 4 acute/subacute side-effects. Two patients with Stage III A central tumors in close proximity to the large vessels died due to a pulmonary hemorrhage 2 and 4 months after therapy, respectively. No patient developed esophagitis. Antimycotic prophylaxis for esophagitis and posttherapeutic steroid prophylaxis for pneumonitis for several weeks were routinely used.
CONCLUSION: The technique of target splitting by asymmetric collimation helps to increase conformation, and thus enhances the sparing of normal tissues. It can be used whenever there is a marked difference in the shape of the planning target volume (PTV) in a cranio-caudal direction. This technique can principally be handled with 2D-planning systems, because it is coplanar. We consider target splitting as an important tool for dose escalation in the primary radiotherapy of NSCLC, that should also be used for other lung cancer patients necessitating moderate doses only.

Entities:  

Mesh:

Year:  1999        PMID: 10760428     DOI: 10.1016/s0360-3016(99)00021-8

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  Non-small cell lung cancer in stages I-IIIB: Long-term results of definitive radiotherapy with doses ≥ 80 Gy in standard fractionation.

Authors:  Karl Wurstbauer; Hannes Weise; Heinz Deutschmann; Peter Kopp; Florian Merz; Michael Studnicka; Olaf Nairz; Felix Sedlmayer
Journal:  Strahlenther Onkol       Date:  2010-09-30       Impact factor: 3.621

2.  Amphotericin B lozengers: prophylaxis for esophagitis in thoracic radiotherapy: a prospective study.

Authors:  Karl Wurstbauer; Florian Merz; Felix Sedlmayer
Journal:  Strahlenther Onkol       Date:  2009-08-04       Impact factor: 3.621

3.  The utility of non-axial treatment beam orientations for lower lobe lung cancers.

Authors:  Brian P Quaranta; Shiva K Das; Timothy D Shafman; Kim L Light; Lawrence B Marks
Journal:  J Appl Clin Med Phys       Date:  2010-01-28       Impact factor: 2.102

4.  Target splitting in radiation therapy for lung cancer: further developments and exemplary treatment plans.

Authors:  Karl Wurstbauer; Heinz Deutschmann; Peter Kopp; Florian Merz; Helmut Schöller; Felix Sedlmayer
Journal:  Radiat Oncol       Date:  2009-08-14       Impact factor: 3.481

5.  DART-bid (Dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily)--a novel approach for non-resected NSCLC: final results of a prospective study, correlating radiation dose to tumor volume.

Authors:  Karl Wurstbauer; Heinz Deutschmann; Karin Dagn; Peter Kopp; Franz Zehentmayr; Bernd Lamprecht; Peter Porsch; Birgit Wegleitner; Michael Studnicka; Felix Sedlmayer
Journal:  Radiat Oncol       Date:  2013-03-05       Impact factor: 3.481

6.  Target splitting non-coplanar RapidArc radiation therapy for a diffuse sebaceous carcinoma of the scalp: a novel delivery technique.

Authors:  Jiang Hu; WeiWei Xiao; ZhiChun He; DeHua Kang; Along Chen; ZhenYu Qi
Journal:  Radiat Oncol       Date:  2014-09-16       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.